FDA panel unanimously backs Novartis' psoriasis drug

October 20, 2014 9:16 PM

4 0

FDA panel unanimously backs Novartis' psoriasis drug

(Reuters) - An advisory panel to the U.S. Food and Drug Administration unanimously recommended the use of Novartis AG's anti-inflammation drug in patients with a type of psoriasis, paving the way for its approval.

The panel voted 7-0 in favor of the drug's use in plaque-psoriasis, the most common form of the painful, unsightly skin condition.

Read more

To category page

Loading...